Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroinflammatory Response Clear all
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 19, 2026, 4:25 PM EDT
Completed No phase listed Observational

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

NCT04094818
View directory record Official record
Conditions
Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
Interventions
TriVerity
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

NCT01823536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Years to 15 Years
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
15
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

NCT01239043
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi
Industry
Eligibility
56 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

NCT00094718
View directory record Official record
Conditions
West Nile Fever Encephalitis
Interventions
WN/DEN4-3'delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

NCT01203345
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions
IVIG, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
2,416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 1991
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 19, 2026, 4:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study Freeze and Transport Immune Cells

NCT00138268
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 19, 2026, 4:25 PM EDT
Not yet recruiting Phase 2 Interventional

THiamine for Recovery In Vulnerable Early-life Infections

NCT07868679
View directory record Official record
Conditions
Meningitis, Bacteremia
Interventions
thiamine hydrochloride 100 mg, Placebo
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 12 Months
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00012467
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Camden, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

NCT00856297
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
MenACWY-CRM conjugate vaccine, Licensed comparator
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
32
States / cities
Birmingham, Alabama • Fremont, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

NCT03674541
View directory record Official record
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance, Dysautonomia, Low Ventricular Filling Pressures (Preload Failure), Postural Orthostatic Tachycardia Syndrome, Orthostatic Hypotension, Fibromyalgia
Interventions
Pyridostigmine Bromide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

NCT00450437
View directory record Official record
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
MenACWY CRM, Meningococcal ACWY Conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 55 Years
Enrollment
3,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 19, 2026, 4:25 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neuroinflammation and Alzheimer's Pathology in POCD

NCT05378659
View directory record Official record
Conditions
Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease
Interventions
Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample
Behavioral · Diagnostic Test
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 19, 2026, 4:25 PM EDT
Terminated Not applicable Interventional Results available

CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies

NCT01440452
View directory record Official record
Conditions
Inflammatory Myelopathies
Interventions
FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment
Device · Procedure · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia

NCT04263454
View directory record Official record
Conditions
Fibromyalgia
Interventions
Endotoxin, Escherichia Coli, Magnetic Resonance Spectroscopy
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 19, 2026, 4:25 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 19, 2026, 4:25 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT05514899
View directory record Official record
Conditions
HIV, Cannabis, THC, Neuroinflammatory Disease, Neuroinflammatory Response, Microbiome
Interventions
THC, CBD
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroinflammation in Chronic Systemic Symptoms (CSS)

NCT04636723
View directory record Official record
Conditions
Cancer, Cancer Head Neck, Neuroinflammatory Response, Chronic Inflammation, Chronic Disease, Chronic Pain
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

NCT00616421
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM, Licensed meningococcal ACWY vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Years to 10 Years
Enrollment
2,907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
52
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 19, 2026, 4:25 PM EDT
Recruiting Not applicable Interventional

Hemorrhage Elimination During Lumbar Puncture Using Ultrasound Measurements (HELPUS)

NCT07612644
View directory record Official record
Conditions
Lumbar Puncture
Interventions
ultrasound contrast
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 12 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

NCT01018732
View directory record Official record
Conditions
Meningococcal Disease, Meningococcal Meningitis
Interventions
Novartis Meningococcal (MenACWY-CRM) vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
16 Years to 23 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 19, 2026, 4:25 PM EDT